Strong pipeline of highly differentiated products
The Lead Discovery Center GmbH (LDC) is working on a broad portfolio of drug discovery projects, small molecules and therapeutic antibodies. The indications include cancer and metabolic syndromes, neurodegenerative diseases, rare diseases, inflammatory disorders and infections, as well as other conditions with high, unmet clinical needs.
TARGET
HIT
LEAD
CANDIDATE
MARKET
TARGET
HIT
LEAD
CANDIDATE
CLINIC
target ID
target validation
assay development
screening
hit-to-lead conversion
lead-to-candidate conversion
PD
PH1
PH2
PH3
NET FORMATION INHIBITORS
GRK5
SLC6A15
GPR81
P2Y6
GLUT
NATA
CYTOLYSIN
KRAS G12D
ASPA
WWC1/2/AMPAR
EPHRIN B2
GCN2
Parkinson's
HTRA1
SFRP1
NTNU1
DRAXIN
RHO GEF
AUTOPHAGY
PDF
IL11-AB
GLI2
FAO
APLK1
SPR
CMT1A
CCL22-AB
MOFi
IMT
COVID
HELICASE INHIBITORS
GABA
CD40/TRAF6
RdRp
GPR182
RiBi
GSDM inhibitors
PCSK6
DM1
DCM
NASH
SULF2
CPT1b
SMGI
Longevity
ATUVECICLIB
ADRIXETINIB
MOCACICLIB
Target 1
Target 2
Target 3
Target 4
Target 5
Target 6
Target 7
Target 8
Target 9
Target 10
Target 11
Target 12
Target 13
Target 14
Target 15
Target 16
REWIND
PEARL RIVER BIO
QLi5 Therapeutics
CALTIC Therapeutics
KinSea Lead Discovery
KyDo Therapeutics
EvlaBio
Tangramed
Cerapeutix
Serengen
Ugisense
Affectis
